Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine
This study will compare the bioavailability and pharmacokinetics of the 0.5 mg, 1 mg and 2.5 mg treprostinil diethanolamine tablet strengths in healthy volunteers.
- Trial name
- NCT01153386
- Testing
- Treprostinil diethanolamine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- United Therapeutics
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the…
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
- Trial name
- RARE-PAH (NCT05584722)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Vanderbilt University Medical Center
Breast Cancer, Cardiovascular Complications
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving bevacizumab may help doctors learn more about changes that occur in DNA and identify biomarkers related to high blood pressure.
- Conditions
- Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01096381
- Testing
- laboratory biomarker analysis, questionnaire administration
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Pulmonary Arterial Hypertension
A Registry for Patients Taking Uptravi
This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi.
- Trial name
- SPHERE (NCT03278002)
- Where
- 85 sites in United States, Puerto Rico
- Volunteers
- 800 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric
Study of PAH Subjects with LTOT Use that have Demonstrated Improved Exercise Tolerance with the use of Inhaled Nitric Oxide
- Trial name
- NCT03602781
- Testing
- iNO
- Where
- 4 sites in United States, Canada
- Sponsor
- Bellerophon Pulse Technologies
Pulmonary Arterial Hypertension
Revatio Special Investigation for Long-term Use in Pediatric Patients
Secondary data collection study: safety and effectiveness of Revatio in pediatric patients under Japanese medical practice
- Trial name
- NCT03364244
- Testing
- Sildenafil
- Where
- Japan
- Volunteers
- 1,023 people
- Sponsor
- Viatris Pharmaceuticals Japan Inc
Hypertension, Pulmonary
Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension
Evaluate the correlation between activity level (monitored by Fitbit Flex remote activity tracker) and 6-minute walk distance (6MWD) (performed by investigator) in patients with Pulmonary Arterial Hypertension (PAH) or Chronic…
- Trial name
- e-MOTION PH (NCT02536534)
- Testing
- Correlation assessment
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
The purpose of this study is to determine if there is a greater effect to patients with advanced pulmonary arterial hypertension (PAH) by using a combination of two drugs, Treprostinil and Riociquat versus Treprostinil alone
- Trial name
- NCT04062565
- Testing
- Treprostinil Injectable Product, Riociguat Pill
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arizona
Pulmonary Vascular Disease, Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Chronic Lung Diseases
The investigators aim to study the effect of liquid oxygen therapy (4l/min, nasal) )in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary…
- Conditions
- Pulmonary Vascular Disease, Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT07777367
- Testing
- 6-minute walk distance (6MWD) test on ambient conditions, 6-minute walk distance (6MWD) test with supplemental oxygen (LOX)
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Arterial Hypertension
An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension
This is a multicenter, open-label trial to evaluate the safety of continued therapy with subcutaneous Remodulin® in subjects with pulmonary arterial hypertension (PAH) who complete the CVT-CV-003 study.
- Trial name
- NCT02882126
- Testing
- Subcutaneous Treprostinil
- Where
- 10 sites in China
- Sponsor
- United Therapeutics
Hypertension, Pulmonary, Connective Tissue Disease
A Study to Evaluate the Use of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
The primary objectives of this exploratory study are to evaluate the effects of bosentan on hemodynamics (via cardiac catheterization) during exercise in patients with Pulmonary Arterial Hypertension (PAH) who have abnormal…
- Trial name
- NCT00864201
- Testing
- bosentan
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Hamilton Health Sciences Corporation
Pediatric Pulmonary Hypertension
Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Children
To analyze the efficacy of beraprost and sildenafil for treatment of pulmonary hypertension in children with left to right shunt. analyze the efficacy and side effects.
- Trial name
- NCT03431649
- Testing
- Beraprost Sodium, Sildenafil Citrate
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- Dr. Soetomo General Hospital
Pulmonary Arterial Hypertension
A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
This proof-of-concept study is designed as a Phase 2, multicenter, randomized, double-blind, placebo controlled study comparing ubenimex with placebo in patients with pulmonary arterial hypertension (PAH) (World Health…
- Trial name
- LIBERTY (NCT02664558)
- Testing
- ubenimex
- Where
- 31 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Eiger BioPharmaceuticals
Pulmonary Vascular Disease, Pulmonary Artery Hypertension
HA Residents With PVD, 6MWD Assessed at HA (2840m) vs LA (Sea Level)
To study the effect of relocation from 2840m (Quito) to sea level (Pedernales) in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH)…
- Conditions
- Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT05996302
- Testing
- Relocation to sea level
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University of Zurich
Idiopathic Pulmonary Hypertension
Efficacy and Safety of Qishen Yiqi Dropping Pills in Patients With Severe Pulmonary Hypertension
This study aims to compare the effectiveness and safety of two treatment approaches for patients with severe pulmonary hypertension: standard targeted drug therapy alone, and a combination of standard targeted drugs plus Qishen…
- Trial name
- NCT07604805
- Testing
- Qishen Yiqi Dropping Pills 0.5g Oral Three Times Daily + Targeted Therapy for Pulmonary Arterial Hypertension, Standard Pulmonary Arterial Hypertension (PAH)-Targeted Therapy Alone
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangdong Provincial People's Hospital
Healthy, Healthy Adult
Assessment of Lung Function (Lufu) at Sea Level LA vs. High Altitude HA in Healthy Individuals
To study the effect of a re-ascent to high altitude (Quito Ecuador: 2850m) after a one-week stay at sea level (after prior descent from 2850m) on lung function and pulmonary resistance/reactance in healthy individuals, who live…
- Conditions
- Healthy, Healthy Adult, High Altitude Effects, High Altitude
- Trial name
- NCT07804537
- Testing
- Re-ascent from sea level to 2850m
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
Arthritis, Asthma
Integrating Behavioral Health and Primary Care for Comorbid Behavioral and Medical Problems
Behavioral problems are part of many of the chronic diseases that cause the majority of illness, disability and death. Tobacco, diet, physical inactivity, alcohol, drug abuse, failure to take treatment, sleep problems, anxiety…
- Conditions
- Arthritis, Asthma, Chronic Obstructive Lung Disease, Diabetes
- Trial name
- IBHPC (NCT02868983)
- Testing
- Integration
- Where
- United States
- Volunteers
- 4,025 people
- Sponsor
- University of Vermont
Pulmonary Arterial Hypertension
CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension
This Phase 2 study (EPIMODE) will evaluate the efficacy and safety of CS1 compared with placebo when added to standard-of-care therapy in participants with pulmonary arterial hypertension.
- Trial name
- EPIMODE (NCT07761572)
- Testing
- CS1
- Volunteers
- 126 people
- Sponsor
- Cereno Scientific AB
Pulmonary Arterial Hypertension
A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging
The purpose of the study is to assess the effects of selexipag on right ventricular (RV) function in participants with Pulmonary arterial hypertension (PAH).
- Trial name
- RESTORE (NCT04435782)
- Testing
- JNJ-67896049
- Where
- 35 sites in United States, Argentina and 13 more
- Volunteers
- 9 people
- Sponsor
- Actelion
Hypertension, Pulmonary
A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)
GSK2586881, a purified intravenous (IV) formulation of soluble recombinant human Angiotensin Converting Enzyme (rhACE2) is being investigated as a treatment for PAH.
- Trial name
- NCT03177603
- Testing
- GSK2586881
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline